METASTATIC OVARIAN CARCINOMA
Clinical trials for METASTATIC OVARIAN CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC OVARIAN CARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC OVARIAN CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for recurrent ovarian cancer in early trial
Disease control OngoingThis early-phase study tests a new drug (berzosertib) added to standard chemotherapy for women with ovarian, peritoneal, or fallopian tube cancer that has returned after initial treatment. The goal is to find the safest dose and see if the combination works better than chemo alon…
Matched conditions: METASTATIC OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:22 UTC
-
New hope for Hard-to-Treat cancers: drug combo trial launches
Disease control OngoingThis early-stage trial tests several new drug combinations in people with advanced solid tumors that have not responded to standard treatments. The goal is to find safe doses and see if these combinations can shrink tumors or slow their growth. About 352 participants with cancers…
Matched conditions: METASTATIC OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:22 UTC
-
Two-Drug combo aims to starve and attack advanced cancers
Disease control OngoingThis early-phase trial tests the safety and best dose of combining two drugs—ziv-aflibercept and pembrolizumab—in people with advanced solid tumors that have spread. Ziv-aflibercept cuts off the tumor's blood supply, while pembrolizumab helps the immune system fight cancer. The s…
Matched conditions: METASTATIC OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:21 UTC
-
New drug combo targets BRCA cancers in early trial
Disease control OngoingThis early-phase trial tests a combination of two drugs—niraparib (a PARP inhibitor) and dostarlimab (an immunotherapy)—in people with BRCA-mutated breast, pancreas, or ovarian cancers that have spread or cannot be surgically removed. The goal is to see if the combo can shrink tu…
Matched conditions: METASTATIC OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: University of Washington • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: METASTATIC OVARIAN CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Blood test may tame Chemo's nerve pain
Knowledge-focused TerminatedThis study looks at whether regularly measuring the amount of paclitaxel (a chemotherapy drug) in the blood can help doctors give the right dose to kill cancer while limiting nerve damage. About 22 adults with various solid tumors (like lung, breast, or ovarian cancer) will have …
Matched conditions: METASTATIC OVARIAN CARCINOMA
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated May 26, 2026 05:28 UTC